Core Viewpoint - Sangfor Pharmaceuticals (01530) shares rose over 6%, currently at HKD 32.58, with a trading volume of HKD 413 million [1] Group 1: Clinical Development - Sangfor Pharmaceuticals announced Phase 2 clinical research data for 707 combination chemotherapy for 1L NSCLC at the 2025 STIC conference [1] - Pfizer has revealed a global clinical strategy for 707, actively advancing its clinical development following an agreement with Sangfor [1] - Pfizer has submitted five new clinical applications for 707, with plans to add ten new indications and over ten novel combination schemes by the end of 2026 [1] Group 2: Financial Performance - Guosen Securities reported that Sangfor's innovative drug clinical progress is rapid, with significant external licensing transactions completed, leading to steady growth in performance [1] - Following the successful licensing of 707, profit forecasts have been raised, with expected net profits for 2025-2027 at CNY 9.955 billion, 2.875 billion, and 3.212 billion respectively [1] - Sangfor's core products are advancing rapidly in global clinical development, maintaining an "outperform the market" rating [1]
港股异动 | 三生制药(01530)现涨超6% 辉瑞将707列为核心管线 计划启动多项临床研究